文献速递肝病消化道肿瘤与早癌

肝移植前肝细胞癌降期:一项全国多中心前瞻性队列研究结果

Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study.
PubMed 文献 · Hepatology · 2025-01-14

该研究纳入5个UNOS区域9个肝移植中心的326例符合UNOS降期标准及190例超出该标准(全纳入)的肝细胞癌患者,前瞻性随访2015至2023年。全纳入组降期成功率66%低于UNOS降期组82%,但移植后5年生存率相似(72% vs 74%),全纳入组复发率更高(30% vs 14%)。

要点

  • 全纳入组2年降期成功率66%,低于UNOS降期组82%(p<0.001)。
  • 全纳入组移植后5年生存率72%与UNOS降期组74%相似,但复发率30%高于14%。
  • 全纳入组中钇-90降期成功率74%高于经动脉化疗栓塞65%。

核心结论

  • 尽管全纳入组肝细胞癌复发率更高且意向治疗生存率更低,全纳入组与UNOS降期组移植后生存率相当。
  • 全纳入组中钇-90降期成功率高于经动脉化疗栓塞。
  • 降期后肝移植在全纳入组可行,但可能有必要界定肿瘤负荷上限。

研究设计与样本

  • 全国多中心前瞻性队列研究,纳入5个UNOS区域9个肝移植中心的患者。
  • 326例符合UNOS降期标准,190例符合全纳入标准,2015至2023年入组并前瞻性随访。
  • 采用竞争风险分析和Kaplan-Meier法评估降期与肝移植结局,Fine-and-Gray和Cox模型识别预测因素。

主要发现

  • 全纳入组与UNOS降期组中位甲胎蛋白相似(15 vs 12 ng/mL;p=0.08)。
  • 全纳入组与UNOS降期组MELD相似(9 vs 9;p=0.52),Child-Pugh相似(A vs A;p=0.30)。
  • 首次局部区域治疗后2年,UNOS降期组82%成功降期,全纳入组66%成功降期(p<0.001)。
  • 全纳入组中,肿瘤数目加最大病灶直径之和<10的降期率为72%,10-12为51%,>12为39%(p=0.01)。
  • 全纳入组中钇-90降期成功率74%高于经动脉化疗栓塞65%(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with HCC meeting United Network for Organ Sharing (UNOS)-downstaging (DS) criteria have excellent post-liver transplantation (LT) outcomes. Studies on HCC beyond UNOS-DS criteria ("All-Comers" [AC]) have been limited by small sample size and short follow-up time, prompting this analysis. APPROACH AND RESULTS: Three hundred twenty-six patients meeting UNOS-DS and 190 meeting AC criteria from 9 LT centers across 5 UNOS regions were enrolled from 2015 to 2023 and prospectively followed. Competing risk analysis and Kaplan-Meier method were used to evaluate DS and LT outcomes, and Fine-and-Gray and Cox models were used to identify predictors of outcomes. AC and UNOS-DS had similar median alpha-fetoprotein (15 vs. 12 ng/mL; p =0.08), MELD (9 vs. 9; p =0.52), and Child-Pugh (A vs. A; p =0.30). Two years after the first local regional therapy, 82% of UNOS-DS and 66% of AC were successfully downstaged ( p <0.001). In AC, DS rates were 72% for tumor number plus diameter of largest lesion <10, 51% for sum 10-12, and 39% for sum >12 ( p =0.01). Yttrium-90 achieved higher DS success than transarterial chemoembolization in AC (74% vs. 65%; p <0.001). 48% of UNOS-DS and 40% of AC underwent LT ( p =0.10). Five-year post-LT survival was similar between UNOS-DS and AC (74% vs. 72%; p =0.77), although 5-year post-LT recurrence was higher in AC (30% vs. 14%; p =0.02). CONCLUSIONS: Despite higher HCC recurrence and lower intention-to-treat survival in AC, post-LT survival was comparable between UNOS-DS and AC. Yttrium-90 attained higher DS success than transarterial chemoembolization in AC. LT after DS is feasible in AC, though defining an upper limit in tumor burden may be necessary.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Xu E, Tabrizian P, Gutierrez J, et al. Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study. Hepatology. 2025. PMID: 39808828. doi:10.1097/HEP.0000000000001231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。